Table 2.
Classes of antiangiogenic agents
| Antiangiogenic mechanisms | Examples |
|---|---|
| Inhibitors of angiogenic factors or receptors | |
| Monoclonal antibodies against angiogenic factors | Bevacizumab (monoclonal anti-VEGF antibody) |
| Antibodies that act as soluble receptors of angiogenic factors | VEGF Trap (Inhibitor of VEGFR1 and VEGFR-2) |
| Inhibitors of tyrosine kinase receptors for angiogenic factors | PTK787/ZK225 (blocks VEGF receptors) |
| SU11248 (blocks VEGFR-1 and -2, FLT3, KIT, PDGFR-α and -β) | |
| BAY43-9006 (blocks VEGFR-2 and 3, PDGFR-β) | |
| Direct inhibitors of endothelial proliferation and survival | |
| Endogenous inhibitors | Endostatin |
| Angiostatin | |
| Exogenous inhibitors | Thalidomide |
| Inhibitors of extracellular matrix breakdown | |
| Inhibitors of matrix metalloproteinases | Marimastat |
| Neovastat | |
| Inhibitors of vascular adhesion molecules | |
| Inhibits integrin αvβ3 receptor | Vitaxin |
Abbreviations: PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.